New strategies for clinical trials in patients with sepsis and septic shock

Critical Care Medicine

Volumn 29, Issue 4, 2001, Pages 880-886

  Cohen, Jonathan ^a,i   Guyatt, Gordon ^b   Bernard, Gordon R ^c   Calandra, Thierry ^d   Cook, Deborah ^b   Elbourne, Diana ^e   Marshall, John ^f   Nunn, Andrew ^g   Opal, Steven ^h  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

^c VANDERBILT UNIVERSITY   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF TORONTO   (Canada)

^g MEDICAL RESEARCH COUNCIL   (United Kingdom)

^h BROWN UNIVERSITY   (United States)

ⁱ HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Clinical trial; Meta analysis; Methods; Sepsis; Septic shock; Statistics

Indexed keywords

ARTICLE; CLINICAL TRIAL; HUMAN; META ANALYSIS; METHODOLOGY; MORBIDITY; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; SCORING SYSTEM; SEPSIS; SEPTIC SHOCK;

EID: 0035054111     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200104000-00039     Document Type: Article

References (38)

1. The epidemiology of bacterial sepsis
2. Incidence, risk factors and outcome of severe sepsis and septic shock in adults: A multicenter prospective study in intensive care units
3. Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK, 1985-1996
4. A one-year survey of nosocomial bacteraemia at a Danish university hospital
5. The sepsis syndrome in a Dutch university hospital. Clinical observations
6. Treating patients with severe sepsis
7. Adjunctive therapy in sepsis: A critical analysis of the clinical trial programme
8. Adjunctive therapy for septic shock: A review of experimental approaches
9. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein
10. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
11. The dynamics of disease progression in sepsis: Markov modeling describing the natural history and likely impact of effective antisepsis agents
12. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study
13. International sepsis trial (INTERSEPT): Role and impact of a clinical evaluation committee
14. Critical evaluation of the design and conduct of previous clinical trials in sepsis
15. CDC definitions for nosocomial infections, 1988
16. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli
17. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial
18. A three-year study of positive blood cultures, with emphasis on prognosis
19. Are there fundamental differences of clinical relevance between Gram positive and Gram negative bacterial sepsis?
20. Microbiologic findings and correlations with serum tumor necrosis factor-α in patients with severe sepsis and septic shock
21. New potential therapeutic modalities: aPC
22. Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
23. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin
24. The detection and interpretation of endotoxaemia
25. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
26. Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis
27. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
28. Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome
29. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: Comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia
30. Monitoring the acute phase response: Comparison of tumour necrosis factor (cachectin) and C-reactive protein in inflammatory and infectious diseases
31. Long-term survival and function after suspected Gram-negative sepsis
32. The siren's songs of confirmatory sepsis trials: Selection bias and sampling error
33. Long-term survival after intensive care unit admission with sepsis
34. The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit
35. The Brussels score
36. Association of TNF2, a TNF-α promotor polymorphism, with septic shock susceptibility and mortality. A multicenter study
37. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock
38. Subgroup analysis and other (mis) uses of baseline data in clinical trials